A Controlled Trial of Mebanazine (‘Actomol’) in Depression
| Autor: | M. David Enoch, I. A. Jan, J.C. Barker |
|---|---|
| Rok vydání: | 1965 |
| Předmět: |
Adult
Male medicine.medical_specialty Monoamine Oxidase Inhibitors Randomization Placebo law.invention Placebos Therapeutic index Randomized controlled trial law Statistical significance Internal medicine Humans Medicine Depression (differential diagnoses) Aged Clinical Trials as Topic Depression business.industry Middle Aged Surgery Psychiatry and Mental health Antidepressant Female business Mebanazine |
| Zdroj: | British Journal of Psychiatry. 111:1095-1100 |
| ISSN: | 1472-1465 0007-1250 |
| DOI: | 10.1192/bjp.111.480.1095 |
| Popis: | The results of this trial do not indicate that patients treated with mebanazine have shown any better response than those given a placebo. Sixty-four percent. of the patients given placebo were "Improved" compared with 52 per cent. of those given mebanazine. These overall results do not differ significantly, but the results for re-admission patients show the proportion of patients "Improved" in the placebo groups to be significantly greater than the proportion "Improved" in the mebanazine group, at the 5 per cent. level of significance. This is a somewhat surprising finding which may be associated with the effects of randomization of treatments to patients at the commencement of the trial. No serious side-effects were encountered in the trial dose of 20 mg. daily. This contrasts with the findings of Cooper and Keddie (1964) who observed instances of serious hypotensive collapse in a dosage of 30 mg. daily. This implies that the therapeutic dose may closely approximate the toxic dose, thus contra-indicating the use of this drug. We are of the opinion that there is some urgency for further controlled trials, perhaps conducted along similar lines, to be undertaken to assess the effectiveness of other antidepressant drugs in current use. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|